抗肿瘤坏死因子-α制剂治疗葡萄膜炎研究进展  

Research update of anti-TNF-a biologic agents in the treatment of uveifis

作　　者：樊帆[1] 周旻[1] 罗怡[1] 

机构地区：[1]复旦大学附属眼耳鼻喉科医院眼科,上海200031

出　　处：《中华眼科杂志》2013年第3期285-288,共4页Chinese Journal of Ophthalmology

摘　　要：葡萄膜炎是临床上常见的致盲性眼病之一，炎症常反复发作，治疗比较棘手。目前认为葡萄膜炎的发病与葡萄膜自身免疫反应密切相关，肿瘤坏死因子（TNF）-α是参与葡萄膜炎发生和发展的关键性细胞因子之一，阻断TNF-α的生成和活性，可抑制视网膜葡萄膜炎的发生和发展。目前主要的抗TNF-α制剂有英夫利昔、阿达木、依那西普及戈利木等。本文就以上制剂在葡萄膜炎治疗中的临床研究、不良反应及与其他免疫抑制剂协同应用原则进行综述。Uveitis is one of the common sight-threatening eye diseases, which is usually recurrent and refractory to treatment. It is generally considered that the development of uveitis is closely related to the autoimmune response of uvea. Tumor necrosis factor （TNF）-ct is one of the key Cytokines involved in the emergence and progression of uveitis. Blocking the production or inhibiting the activity of TNF-α can inhibit the development or progression of uveititis. Presently, the commercially available TNF-α blockers include infliximab, adalimumab, etanercept, and golimumab. This review describes the clinical studies and adverse effects of TNF-α blockers in the treatment of uveitis, and discusses the principle for clinical use of TNF-α blockers in synergy with other immunosuppressive agents.

关 键 词：葡萄膜炎 肿瘤坏死因子α 抗体 单克隆 免疫球蛋白G 受体 肿瘤坏死 因子 

分 类 号：R773[医药卫生—眼科]